Rapid sequence intubation medication sequence in children — premedication, induction agent selection by hemodynamics, and weight-based paralytic dosing
Pediatric rapid sequence intubation (RSI) succeeds or fails largely on what happens before the first medication is pushed. Children desaturate far faster than adults during apnea because of higher weight-relative oxygen consumption and lower functional residual capacity — the safety window between "paralyzed" and "hypoxic" can be a matter of seconds in a small infant. The preparation phase exists to widen that window as much as physiology allows.
Pediatric RSI preparation is commonly organized around a checklist mnemonic — Suction, Oxygen, Airway equipment, Pharmacology, Monitors, Equipment (SOAP-ME):
• Suction: functioning, within reach, appropriate catheter size • Oxygen: source connected, bag-valve-mask sized to the child, high-flow nasal cannula available for apneic oxygenation • Airway equipment: laryngoscope blades (straight blade commonly preferred in infants/young children), endotracheal tubes in the calculated size plus one size above and below, stylet, bougie, supraglottic rescue device, and a surgical airway kit for the "can't intubate, can't oxygenate" contingency • Pharmacology: every drug in the sequence drawn up, labeled, and dosed to the child's actual or estimated weight — not guessed • Monitors: continuous SpO₂, ECG, automated or arterial blood pressure, and waveform capnography ready to confirm placement the moment the tube is in • Equipment: suction, backup airway devices, and a plan for difficult airway escalation
Because children span a huge size range, equipment must be selected by weight or length-based tape (e.g. Broselow) rather than by "typical adult" assumption. A commonly used estimate for uncuffed tube internal diameter is age(years)/4 + 4 mm, with cuffed tubes roughly half a size smaller; tube depth at the lip is often estimated as age/2 + 12 cm. These are starting estimates to be confirmed clinically and radiographically, not fixed rules.
Pre-oxygenation aims to fill the functional residual capacity (FRC) with oxygen, creating a reservoir the child draws from during the apneic period between induction/paralysis and successful tube placement. In a cooperative or already-monitored child, 3–5 minutes of tidal breathing on a non-rebreather mask or gentle bag-valve-mask support, targeting SpO₂ >95%, is typical practice.
Children desaturate faster than adults during apnea for two compounding reasons: their oxygen consumption per kilogram is roughly double that of an adult (higher metabolic rate, higher minute ventilation requirement), while their FRC — the oxygen reservoir itself — is proportionally smaller. The combination means the safe apnea window can shrink from several minutes in an adult to well under a minute in a small infant.
Apneic oxygenation — leaving low-flow or high-flow nasal cannula oxygen running throughout the procedure, including after paralysis — is a widely used adjunct that can meaningfully extend the desaturation-free interval by maintaining a passive oxygen gradient in the pharynx even when the child is not actively breathing.
The preparation phase is where the entire procedure's margin for error is set. No induction or paralytic dosing strategy can compensate for equipment that is the wrong size or monitoring that is not yet running — preparation is the true first "dose" of safety in pediatric RSI.
Unlike a healthy adult, an infant's cardiac output is far more dependent on heart rate than on stroke volume, because the immature ventricle has limited compliance and cannot substantially increase the volume it ejects per beat. That physiology makes procedural bradycardia — triggered by vagal stimulation from laryngoscopy or by succinylcholine itself — a much higher-stakes event in young children than in older patients, and it is the reasoning behind premedication with an anticholinergic such as atropine in selected cases.
The physiologic argument for premedication rests on a simple relationship: cardiac output equals heart rate multiplied by stroke volume. In infants and young toddlers, the ventricle is stiffer and less able to augment stroke volume, so a sudden drop in heart rate translates almost directly into a drop in cardiac output and perfusion — there is little compensatory reserve.
Two triggers are classically implicated in procedural bradycardia during RSI:
• Vagal stimulation from direct laryngoscopy itself, particularly with repeated or prolonged attempts • Succinylcholine, a depolarizing paralytic with cholinergic (vagotonic) effects that can cause bradycardia, especially with a second dose
Atropine (an anticholinergic) is the drug most often considered to blunt this response, at a typical dose of 0.02 mg/kg IV, with a minimum single dose observed to avoid a paradoxical bradycardia phenomenon seen with very small doses. Groups most often discussed as candidates for consideration include infants (commonly cited as under 1 year of age), children receiving a second dose of succinylcholine, and those with a prior history of significant procedural bradycardia.
Historical pediatric RSI teaching often called for atropine before every intubation in young children as a routine step. Practice has shifted over time toward a more selective approach: many current protocols reserve premedication for the higher-risk groups described above rather than applying it universally, reflecting accumulating evidence that routine use in all children does not clearly change outcomes and that the drug carries its own effects (tachycardia, pupillary dilation that can confound neurologic exam, dry secretions).
Regardless of whether atropine is given prophylactically, it should be immediately available and drawn up at the bedside for every pediatric RSI, because it remains the direct treatment for clinically significant bradycardia that develops during the procedure — the goal of "premedication consideration" is really a broader readiness question: is the team prepared to recognize and treat a heart-rate-dependent child's bradycardia the instant it appears, whether or not a dose was given in advance.
Premedication is not about a mandatory drug — it is about matching the plan to the physiology. A team that has decided against prophylactic atropine but has it drawn up and ready is prepared; a team that gave it routinely without a plan for other bradycardia triggers is not.
The three induction agents most commonly used in pediatric RSI — ketamine, etomidate, and propofol — share the goal of rapid unconsciousness but differ sharply in their cardiovascular effects. Selecting among them is less about a single "best" drug and more about matching each agent's hemodynamic profile to the physiologic state of the specific child in front of you, especially whether that child is in shock.
Ketamine (typical dose ~1–2 mg/kg IV) is a dissociative agent that, unlike most sedative-hypnotics, tends to increase or preserve heart rate and blood pressure through catecholamine release, and it largely preserves airway reflexes and respiratory drive. This profile makes it the most commonly favored induction agent in hypotension, shock, or hemodynamic instability. It also has bronchodilatory properties that are useful in reactive airway disease/status asthmaticus. A caveat: in a patient who is catecholamine-depleted (prolonged, severe shock), ketamine's direct myocardial depressant effect can become unmasked, so it is not a guarantee of hemodynamic stability in every unstable child.
Etomidate (typical dose ~0.2–0.3 mg/kg IV) is prized for producing minimal change in heart rate or blood pressure across a broad range of patients, making it a frequently used "hemodynamically neutral" choice. Its main controversy is transient adrenal cortisol suppression after even a single dose, which has generated ongoing debate about its use in septic shock specifically, where endogenous cortisol response may already be compromised.
Propofol (typical dose ~1–2.5 mg/kg IV) offers very rapid onset/offset and useful antiemetic and anticonvulsant properties, but it causes dose-dependent vasodilation and can blunt cardiac contractility — effects that can produce significant, sometimes profound, hypotension in a volume-depleted or already-hypotensive child. It is generally reserved for hemodynamically stable children.
Hemodynamic status is the dominant decision axis, but other clinical contexts refine the choice further:
• Septic shock: ketamine is frequently favored over etomidate given the adrenal suppression debate, though the clinical significance of a single etomidate dose in this population remains actively discussed in the literature • Status asthmaticus / severe bronchospasm: ketamine's bronchodilatory effect is an added reason to favor it independent of hemodynamics • Elevated intracranial pressure / traumatic brain injury: ketamine was historically avoided due to concern about raising ICP, but more recent evidence in ventilated, hemodynamically supported patients has softened that concern considerably; etomidate has traditionally been favored here for its hemodynamic neutrality, which helps protect cerebral perfusion pressure • Hemodynamically stable, elective-like RSI: propofol or etomidate are both reasonable, with the choice often driven by institutional familiarity and specific comorbidities rather than a hard rule
An adjunct worth noting: opioids such as fentanyl are sometimes added to blunt the sympathetic surge of laryngoscopy in specific scenarios (e.g. elevated ICP), but this must be weighed carefully against the added risk of hypotension, particularly when combined with propofol.
There is no universally "correct" induction agent in pediatric RSI. The question is never "which drug is best" in the abstract — it is "which drug's cardiovascular profile this specific, physiologically deranged child can tolerate."
The paralytic is what actually enables intubation — it eliminates airway reflexes and jaw/vocal cord tone. The two agents in practical use, succinylcholine (depolarizing) and rocuronium (non-depolarizing), are both dosed strictly by weight but differ substantially in onset, duration, and the contraindications a clinician must screen for before pushing either one.
Both agents are dosed strictly per kilogram of body weight, and infants often require a proportionally higher succinylcholine dose per kilogram than adults (commonly cited around 2 mg/kg in infants versus roughly 1–1.5 mg/kg in older children/adults) because of a larger relative extracellular fluid volume of distribution.
Succinylcholine (depolarizing): onset ~45 seconds, clinical duration roughly 5–10 minutes. Its short duration is often framed as a safety feature — if intubation fails and the airway cannot be secured, spontaneous respiration may return relatively quickly. That same short duration is not a guarantee of oxygenation, however: a child who cannot be bag-mask ventilated will still desaturate well before paralysis wears off.
Rocuronium (non-depolarizing): onset roughly 60 seconds at RSI dosing (1–1.2 mg/kg), with a much longer clinical duration of approximately 45–70 minutes. Because there is no built-in "self-rescue" from a failed airway during that window, the decision to use rocuronium carries an implicit commitment: the team must be highly confident it can either intubate or effectively bag-mask ventilate for well over half an hour if needed. Where available, sugammadex can rapidly reverse rocuronium-induced paralysis in a true failed-airway emergency, which has shifted some practices toward rocuronium even outside elective contexts.
Succinylcholine carries several contraindications that must be actively screened for, because they are not always evident on a quick history:
• Hyperkalemia risk states: burns older than roughly 5 days, crush injury, major muscle trauma, prolonged immobilization, and pre-existing neuromuscular disease (e.g. muscular dystrophy) — succinylcholine can trigger dangerous, sometimes lethal, hyperkalemia in these settings • Personal or family history suggestive of malignant hyperthermia • Known or suspected myopathy • Recent significant burn or denervation injury
Rocuronium has a much shorter contraindication list (primarily known hypersensitivity), which is part of why it has become the more commonly reached-for default paralytic in many pediatric RSI protocols — but its long duration means the airway plan absolutely must not depend on the paralysis wearing off as a backup strategy.
In practice, the paralytic decision is made jointly with the induction agent and the pre-formed airway backup plan: what will the team do if the tube cannot be placed on the first, second, or third attempt, and does the chosen paralytic's duration match how long that backup plan can be sustained safely.
Choosing a paralytic is really choosing a commitment window. Succinylcholine buys a short one with real contraindications to screen; rocuronium buys pharmacologic simplicity at the cost of a long commitment that only sugammadex can shorten. Neither choice is complete without a rehearsed failed-airway plan.
Successfully passing the tube is not the end of the medication sequence — it is the point where a new, equally dangerous risk begins. The paralytic given minutes earlier is often still fully active, and unless sedation and analgesia are started immediately, the child can be left fully conscious and aware while completely unable to move, breathe on their own, or signal distress.
Continuous waveform capnography is the gold-standard confirmation that the endotracheal tube is in the trachea and not the esophagus — a sustained, characteristic CO₂ waveform on every breath is far more reliable than any single clinical sign alone. This is paired with the traditional clinical exam: bilateral, symmetric breath sounds, visible and symmetric chest rise, absence of gastric sounds on epigastric auscultation, and fogging in the tube during exhalation as a lower-confidence supporting sign.
Once placement is confirmed, the tube is secured at an estimated depth (a common rough estimate is age/2 + 12 cm at the lip for children over roughly 2 years, alongside weight/age-based nomograms for younger children) and depth is subsequently verified with a chest radiograph, aiming for the tube tip well above the carina.
This is the step most likely to be delayed under the pressure of a successful, adrenaline-charged intubation — and it is arguably the single most important patient-safety action left in the sequence. If a long-acting non-depolarizing paralytic such as rocuronium was used, the child may remain paralyzed for 45–70 minutes. Without prompt sedation and analgesia, that child is conscious, feels pain and the sensation of the tube, and cannot move a muscle to indicate it: a state sometimes described as "awake paralysis," and a well-recognized source of significant psychological trauma when it occurs.
A typical approach pairs an analgesic (commonly an opioid such as fentanyl) with a sedative-hypnotic (such as a benzodiazepine like midazolam, or a continuous propofol infusion in a hemodynamically stable child), titrated to a validated sedation scale rather than fixed doses alone. The infusion or intermittent dosing plan should be established as part of the pre-procedure plan — not improvised only after the tube is confirmed — precisely because there is so little margin for delay once the airway is secured.
Ongoing management continues with reassessment of vitals, ventilator settings appropriate to the child's size and pathology, repeat clinical and radiographic confirmation of tube position, and close monitoring for the return of paralytic effect, hemodynamic drift, or the need for additional sedation.
The most dangerous moment in pediatric RSI is not the laryngoscopy — it is the ten minutes after a successful intubation when attention shifts to documentation and reassessment, and post-intubation sedation quietly does not get started. Build the sedation plan and have the syringes ready before the paralytic is even pushed.